Efficacy of Percutaneous Ethanol Injection Therapy in Korean with Hepatocellular Carcinoma / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 502-509, 2003.
Article
in Korean
| WPRIM
| ID: wpr-96873
ABSTRACT
BACKGROUND/AIMS:
Percutaneous ethanol injection therapy (PEIT) is widely used for the treatment of hepatocellular carcinoma (HCC). However, its long-term therapeutic efficacy is not verified in Korea, one of hepatitis B virus (HBV) endemic areas. Thus, this study was to assess its efficacy and prognostic factors affecting tumor-free survival following PEIT in Korean HCC patients.METHODS:
From 1997 to 1999, 100 consecutive patients who had 1 to 3 HCC nodules of maximum diameter less than 3 cm and underwent PEIT were enrolled. Therapeutic efficacy, overall and tumor-free survival rates were assessed during follow-up periods.RESULTS:
In 83 patients, HCC nodules were completely ablated by PEIT. The cumulative 1, 2, and 3 year overall survival rates were 98%, 96%, and 88%, respectively. The cumulative 1, 2, and 3 year tumor-free survival rates were 73%, 50%, and 37%, respectively. Larger tumors (> or = were associated with a higher local recurrence rate.CONCLUSIONS:
These results demonstrate that PEIT is therapeutically useful in patients with HCC less than 4 in number and less than 3 cm in diameter. However, since multiple or large tumors are associated with low tumor-free survival or high local recurrence rates, PEIT for these tumors and the subsequent post-treatment follow-up should be performed carefully.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Injections, Intralesional
/
Survival Rate
/
Carcinoma, Hepatocellular
/
Ethanol
/
Korea
/
Liver Neoplasms
/
Neoplasms, Multiple Primary
Type of study:
Prognostic study
Limits:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
Korean
Journal:
The Korean Journal of Gastroenterology
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS